For the quarter ending 2026-03-31, PROF made $5,337K in revenue. -$8,058K in net income. Net profit margin of -150.98%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue (note 12) | 5,337 | 5,977 | 5,289 | 2,211 |
| Cost of sales | 1,505 | 1,986 | 1,358 | 593 |
| Gross profit | 3,832 | 3,991 | 3,931 | 1,618 |
| Research and development | 5,262 | 4,272 | 5,418 | 6,098 |
| Selling, general and administrative | 6,591 | 7,088 | 7,426 | 9,326 |
| Total operating expenses | 11,853 | 11,360 | 12,844 | 15,424 |
| Operating loss | -8,021 | -7,369 | -8,913 | -13,806 |
| Net finance (income) expense | 377 | 160 | 122 | 343 |
| Net foreign exchange (gain) loss | 616 | -939 | 935 | -2,168 |
| Total other (income) expenses | 993 | -779 | 1,057 | -1,825 |
| Net loss before income taxes | -7,028 | -8,148 | -7,856 | -15,631 |
| Income tax expense | 27 | 12 | 100 | 78 |
| Deferred tax expense (recovery) | -2 | 14 | 21 | -14 |
| Total income tax expense | 25 | 26 | 121 | 64 |
| Net loss attributed to shareholders for the period | -7,053 | -8,174 | -7,977 | -15,695 |
| Foreign currency translation adjustment | -1,005 | 275 | -808 | 2,713 |
| Net loss and other comprehensive loss for the period | -8,058 | -7,899 | -8,785 | -12,982 |
| Basic EPS | 0.19 | -0.257 | 0.26 | 0.52 |
| Diluted EPS | 0.19 | -0.257 | 0.26 | 0.52 |
| Basic Average Shares | 36,297,684 | 30,732,490 | 30,104,497 | 30,053,142 |
| Diluted Average Shares | 36,297,684 | 30,732,490 | 30,104,497 | 30,053,142 |
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)